BACKGROUND: Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well described. METHODS: We retrospectively examined outcomes after combined modality therapy including thoracic radiation therapy (RT) in 123 patients with locally advanced NSCLC and known EGFR mutation status. Outcomes were compared using Kaplan-Meier analysis, the log-rank test, and multivariate Cox regression models. RESULTS: All 123 patients underwent thoracic RT; 25% had tumors with EGFR mutations and 94% had stage III disease. Overall, 81% received chemotherapy concurrent with RT and 55% underwent surgical resection. With a median follow-up of 27.5 months, the overall survival (OS) rate was significantly higher in patients with EGFR-mutant tumors than in those with wild-type EGFR tumors (2-year estimate: 92.6% versus 69.0%; p = .04). The 2-year relapse-free survival and distant recurrence rates did not differ significantly by genotype. The 2-year locoregional recurrence rate (LRR) was significantly lower in EGFR-mutant than in wild-type EGFR patients (17.8% versus 41.7%; p = .005). EGFR-mutant genotype was associated with a lower risk for LRR on multivariate analysis, but not OS, after adjusting for surgery and other potential confounders. CONCLUSION: We observed that EGFR-mutant patients with locally advanced NSCLC treated with RT had lower rates of LRR than wild-type EGFR patients, raising the hypothesis that EGFR mutations may confer sensitivity to RT and/or chemotherapy. The association between mutation status and OS after combined modality therapy was less robust. Our data may serve as a useful baseline estimate of outcomes by EGFR genotype for future prospective studies.
BACKGROUND:Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLCpatients have not been well described. METHODS: We retrospectively examined outcomes after combined modality therapy including thoracic radiation therapy (RT) in 123 patients with locally advanced NSCLC and known EGFR mutation status. Outcomes were compared using Kaplan-Meier analysis, the log-rank test, and multivariate Cox regression models. RESULTS: All 123 patients underwent thoracic RT; 25% had tumors with EGFR mutations and 94% had stage III disease. Overall, 81% received chemotherapy concurrent with RT and 55% underwent surgical resection. With a median follow-up of 27.5 months, the overall survival (OS) rate was significantly higher in patients with EGFR-mutant tumors than in those with wild-type EGFRtumors (2-year estimate: 92.6% versus 69.0%; p = .04). The 2-year relapse-free survival and distant recurrence rates did not differ significantly by genotype. The 2-year locoregional recurrence rate (LRR) was significantly lower in EGFR-mutant than in wild-type EGFRpatients (17.8% versus 41.7%; p = .005). EGFR-mutant genotype was associated with a lower risk for LRR on multivariate analysis, but not OS, after adjusting for surgery and other potential confounders. CONCLUSION: We observed that EGFR-mutant patients with locally advanced NSCLC treated with RT had lower rates of LRR than wild-type EGFRpatients, raising the hypothesis that EGFR mutations may confer sensitivity to RT and/or chemotherapy. The association between mutation status and OS after combined modality therapy was less robust. Our data may serve as a useful baseline estimate of outcomes by EGFR genotype for future prospective studies.
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Kathy S Albain; John J Crowley; Andrew T Turrisi; David R Gandara; William B Farrar; Joseph I Clark; Kristie R Beasley; Robert B Livingston Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: Benjamin Solomon; Jim Hagekyriakou; Melanie K Trivett; Steven A Stacker; Grant A McArthur; Carleen Cullinane Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: David R Gandara; Kari Chansky; Kathy S Albain; Bryan R Leigh; Laurie E Gaspar; Primo N Lara; Howard Burris; Paul Gumerlock; J Philip Kuebler; James D Bearden; John Crowley; Robert Livingston Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Amit K Das; Benjamin P Chen; Michael D Story; Mitsuo Sato; John D Minna; David J Chen; Chaitanya S Nirodi Journal: Cancer Res Date: 2007-06-01 Impact factor: 12.701
Authors: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate Journal: EMBO Mol Med Date: 2010-05 Impact factor: 12.137
Authors: David M McClatchy; Henning Willers; Aaron N Hata; Zofia Piotrowska; Lecia V Sequist; Harald Paganetti; Clemens Grassberger Journal: Cancer Res Date: 2020-09-09 Impact factor: 12.701
Authors: Raymond H Mak; Gretchen Hermann; John H Lewis; Hugo J W L Aerts; Elizabeth H Baldini; Aileen B Chen; Yolonda L Colson; Fred H Hacker; David Kozono; Jon O Wee; Yu-Hui Chen; Paul J Catalano; Kwok-Kin Wong; David J Sher Journal: Clin Lung Cancer Date: 2014-09-30 Impact factor: 4.785
Authors: Mun Sem Liew; Joseph Sia; Maud H W Starmans; Ali Tafreshi; Sam Harris; Malcolm Feigen; Shane White; Allan Zimet; Philippe Lambin; Paul C Boutros; Paul Mitchell; Thomas John Journal: Cancer Med Date: 2013-10-16 Impact factor: 4.452
Authors: Dong Soo Lee; Jin Hyoung Kang; Chang Geol Lee; Seoung Jun Kim; Young Jin Choi; Kyo Young Lee; Yeon Sil Kim Journal: Cancer Res Treat Date: 2013-06 Impact factor: 4.679